Trial intelligence / Profile preview

DAN-CART 1901 for relapsed/refractory CD19-positive hematologic malignancies

2024-515174-27-00Phase 2Authorised

Sponsor: Rigshospitalet
Start: Oct 2022
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Countries: 1

Overview

Phase 2, open-label, single-arm trial of DK-CLIC-1901 in B cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphoma, follicular lymphoma (FL) and 8 more, sponsored by Rigshospitalet. Primary endpoints: Cytokine release syndrome, ICANS and 5 more. Planned start Oct 2022; status: authorised.

Drugs

DK-CLIC-1901

Conditions

B cell acute lymphoblastic leukemia (B-ALL)mature B-cell lymphomafollicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)

Beyond the preview

Go deeper on 2024-515174-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-515174-27-00.